Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
European Journal of Haematology|November 20, 2009
Antibody buffering of systemically administered lysozymeCarol O'Hear, Jefferson FooteJournal of Molecular Biology|October 19, 2006
Antibody buffering in the brainCarol O'Hear, Jefferson FooteExpert Review of Hematology|May 30, 2014
Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?Carol O'Hear, Jeffrey E RubnitzHaematologica|December 7, 2014
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemiaCarol O'Hear, Joshua F Heiber, Ingo Schubert, et al.Journal for Immunotherapy of Cancer|October 25, 2019
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumabLuciana Molinero, Yijin Li, Ching-Wei Chang, et al.Journal of Neuro-Oncology|August 4, 2018
Clinical activity and safety of atezolizumab in patients with recurrent glioblastomaRimas V Lukas, Jordi Rodon, Kevin Becker, et al.JAMA Oncology|February 10, 2018
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 StudyDaniel P Petrylak, Thomas Powles, Joaquim Bellmunt, et al.Cancer|September 6, 2013
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemiaCarol O'Hear, Hiroto Inaba, Stanley Pounds, et al.JAMA Ophthalmology|November 2, 2018
Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal VenulitisLeisha A Emens, S Lindsey Davis, Scott C N Oliver, et al.Clinical Lung Cancer|June 27, 2020
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung CancerAnne C Chiang, Lecia Van Dam Sequist, Jill Gilbert, et al.Pageof 2